"Successful integrated development of a small molecule to treat autoimmune diseases resulted in readiness for patient testing in Phase 2, with the involvement of Venn’s CMC, non-clinical, and clinical development teams, including end-to-end support, trial execution, and oversight."
Clinical-stage Biopharmaceutical Company
October 2023